This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Zions Bancorporation (ZION - Free Report) and its subsidiary’s ratings have been affirmed by Moody’s Investors Service, the rating arm of Moody’s Corporation (MCO - Free Report) . The outlook for the company has been upgraded to positive from stable. Zions’ senior unsecured rating has been affirmed at (P)Baa3. Its subsidiary’s Baseline Credit Assessment (BCA) stands at baa2 while its issuer rating has been affirmed at Baa3.
ELY ZIONW GBNK ICFI SIVB MCO ZBK ZION GUAA ZIONZ
Document UNITED STATES
Welcome to the Fiserv 2018 second quarter earnings conference call. All participants will be in a listen-only mode until the question-and-answer session begins following the presentation. As a reminder, today's call is being recorded.
FISV ZBK ZION ZIONW ZIONZ
SVB Financial Group’s (SIVB - Free Report) second-quarter 2018 earnings of $4.42 per share significantly outpaced the Zacks Consensus Estimate of $3.86. Also, the figure compared favorably with the prior-year quarter’s earnings of $2.32 per share. Results were primarily driven by higher net interest income (NII) and non-interest income. Moreover, loan and deposit balances reflected strength. However, higher non-interest expenses and a drastic surge in provision for credit losses acted as headwinds.
CBSH ZIONW FRC SIVB SAM ZBK ZION EMN NVR TRN ZIONZ
Prosperity Bancshares Inc.’s (PB - Free Report) second-quarter 2018 earnings of $1.17 per share surpassed the Zacks Consensus Estimate of $1.15. Moreover, the figure improved 18.2% on a year-over-year basis. Results were primarily driven by an improvement in revenues. Also, increasing loan balances supported results to some extent. However, an increase in expenses and higher provisions were the undermining factors.
CBSH ZIONW CBSHP FRC CBCB PB ZBK ZION ZIONZ
Good day, ladies and gentlemen, and welcome to the Zions Bancorporation Second Quarter 2018 Earnings Results Webcast. At this time, all participants are in a listen-only mode. Later, we will conduct the question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, this conference call is being recorded.
ZBK ZION ZIONW ZIONZ
Most banks that reported second-quarter 2018 results this week managed to record bottom-line improvement on the back of rising rates, lower provisions and improved trading activities. This also led to positive price movement for most bank stocks over the last five trading days. In addition to the benefits from higher interest rates, banks’ results mirrored a marginal upswing in loans. Moreover, the results display eased margin pressure.
WFCNP HBANN ZIONW HBANO HBANP FITBI PB BAC USB ZBK ZION BKU WFC BAC C HBAN FITB CFR ZIONZ
Zions Bancorporation (ZION - Free Report) is scheduled to announce second-quarter 2018 results on Jul 23, after the market closes. Its revenues and earnings for the quarter under review are projected to grow year over year. In the last reported quarter, Zions’ earnings outpaced the Zacks Consensus Estimate. Higher revenues and benefit from provisions aided results. However, higher adjusted non-interest expenses were the undermining factor.
ZBK ZION ZIONW BKU HTH SIVB ZIONZ
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
2018-08-13 - Asif
Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...
as of ET